Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.36

    ▲ −0.14 (−1.12%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ −0.06 (−12.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

InMed Pharmaceuticals — 14 videos in collection

More on this equity

In this video, InMed’s CEO Eric A Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.

< Previous
Next >

You may also be interested in these:

Healthcare

InMed Pharmaceuticals: Edison Open House Healthcare 2022

Healthcare

InMed Pharmaceuticals – Introducing the BayMedica team

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free